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1. Introduction 
1.1 Introduction to placenta 
The placenta is a highly specialized organ with a limited life span. It is unique to 
mammals, and in concert with fetal membranes and amniotic fluid it supports the 
normal growth and development of the fetus (1). Placenta is quite remarkable as it 
performs multiple functions, which in the adult are associated with several individual 
organs. The transfer of respiratory gases and nutrients between mother and fetus are 
functions analoguous to those of the lung and intestine respectively, while the 
handling and transport of fetal waste products is analogue to the kidney. Substances 
transported to the fetus include amino acids, carbohydrates, lipids, vitamins, minerals, 
water and oxygen. Reverse transport of metabolic waste products to the maternal 
circulation include carbon dioxide and urea (reviewed in (2)). In addition it is an 
important endocrine gland, which biosynthesis hormones that are essential to the 
maintenance of pregnancy (3). These placental functions serve as substitutes for the 
developing fetal organs until they are mature enough to fulfil the functions on their 
own. Other placental functions include energy metabolism to support placental needs, 
metabolic modifications of maternal nutrients destined for the fetus, maintenance of 
an immunological barrier, transfer of heat, and detoxification of xenobiotics.  
 
There are large species variations in placental architecture. Histologically humans 
and rodents have a placenta where the maternal blood comes into direct contact with 
the trophoblast cells. Still the human placenta differs from that of rodents in that only 
a single layer of trophoblast cells separate the fetal endothelial cells from direct 
contact with the maternal blood. At term, the average normal human placenta is ~22 
cm in diameter, 2-2.5 cm thick and with a weight of ~500 grams (Figure 1).  
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Figure 1: Human third trimester placenta; seen from the fetal side including the umbilical 
cord. From www.wikipedia.org 
1.1.1 Development of the placenta 
The fertilized egg develops into a blastocyst with an inner cell mass that becomes the 
fetus. The outer layer of cells consist of trophoblast cells. They invade the uterine 
wall (endometrium) in a highly regulated process and have a crucial role both in 
implantation and placentation (Figure 2, (1)). They develop into the placenta (which 
is fetally derived) and the fetal membranes (Figure 2). Failure to control the invasion 
of the trophoblasts results in a very aggressive cancer, named choriocarcinoma (4). 
The maternal part of the placenta, the decidua basalis, is the term for the uterine 
lining during pregnancy that is developed from the endometrium (Figure 3, (5)). The 
trophoblasts from the outer layer of the blastocyst eventually differentiate into either 
villous or extravillous trophoblasts. The extravillous trophoblasts invade the decidua 
and remodel the uterine spinal arteries to accommodate the increased blood flow 
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needed during gestation. Insufficient trophoblast invasion with altered remodeling of 
the spiral arteries is a common feature of preeclampsia (6).  
 
 
 
 
 
 
 
 
 
Figure 2: Implantation of the blastocyst. The trophoblast outer layer of the blastocyst forms 
an attachment with the endometrium about 6 days after fertilization in humans.  
 
The villous trophoblasts consist of two cell populations, the cyto- and the 
syncytiotrophoblasts. The cytotrophoblasts proliferate, differentiate and subsequently 
fuse to multinuclear syncytiotrophoblasts (Figure 3). The finger-like chorionic villi 
are the functional units of the placenta and are surrounded by maternal blood in the 
intervillous space provided by the transformed uterine spiral arteries (Figure 3). The 
villi bring the maternal and fetal side in close proximity, and are constructed to give 
maximal area of contact between the fetal and maternal blood for efficient feto-
maternal exchange (Figure 3). In the beginning of pregnancy, the villi consist of both 
a cyto- and a syncytiotrophoblast layer, but the cytotrophoblasts gradually disappear 
throughout gestation (reviewed in (1;2)). Despite having a key role in active 
Trophoblast cells
Inner cell mass
Blastocyst before
implantation
Start of implantation
Trophoblast cells
Trophoblast cells 
invading the uterine wall 
uterine wall
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transport, hormone biosynthesis and metabolic regulation, the syncytiotrophoblasts 
have been thought to be transcriptionally inactive. Very recently this hypothesis was 
challenged by the finding of nucleoside incorporation and histone modifications 
associated with active chromatin and potential transcriptional activity in these cells 
(7). 
  
 
 
 
 
 
 
 
 
Figure 3: The villous structure of placenta. The villi, the functional units of the placenta are 
surrounded by maternal blood from the transformed spiral arteries of the uterine wall. The 
villi consist of an outer layer of syncytiotrophoblasts and an inner layer of cytotrophoblasts. 
Modified from www.wikipedia.com 
 
1.1.2 Placenta endocrine functions - biosynthesis of human 
chorionic gonadotropin  
Because the placenta is not innervated, communication with the mother and fetus is 
mainly through the biosynthesis and secretion of hormones and other substances into 
the circulations. The human placenta produces estrogens, progesterone, human 
chorionic gonadotropin (hCG), human placental lactogen (hPL), placental growth 
Villous structures Decidua basalis
Villous structure
Syncytiotrophoblasts
Cytotrophoblasts
Blood vessels
Spiral artery
Umbilical cordFetus
Intervillous space
with maternal blood
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hormone, as well as a number of growth factors, cytokines, chemokines, eicosanoids 
and many others (reviewed in (2)). The two main steroid hormones biosynthesized in 
placenta are estrogen and progesterone, while hCG and hPL are two of the main 
peptide/protein hormones biosynthesized by the placenta (1).  
hCG is a glycoprotein composed of two subunits ( and ) non-covalently joined 
together (8;9). It is produced by the syncytiotrophoblasts mainly in early pregnancy 
with peak plasma levels at about 8 weeks of gestation, and secreted into mainly the 
maternal circulation (10). It promotes the corpus luteum progesterone production 
until the placenta develops sufficient production of progesterone to maintain 
pregnancy (10). hCG increases cytotrophoblast differentiation and placental 
angiogenesis, functions that are critical for efficient placentation in humans (11-13).  
1.1.3 Maternal and fetal lipid changes in healthy pregnancies 
Pregnancy is a metabolically dynamic situation that can be divided into two 
metabolically different periods, an anabolic period in early and mid pregnancy 
followed by a catabolic period at the end of pregnancy. During the anabolic period 
there is limited fetal growth and maternal hyperphagia which promote the 
accumulation of maternal body fat (14;15). The catabolic period is simultaneous with 
the period of maximal fetal growth, when most of the fat deposition in the fetus 
occurs (Figure 4). At this stage there is an increased maternal adipose tissue lipolysis 
and increased circulating free fatty acids (FFAs, Figure 4 (15;16)). This is thought to 
be secondary to the development of insulin resistance (17), which is a normal feature 
of a healthy pregnancy (reviewed in (18)). Much of the FFA are taken up by the liver, 
activated to acyl-Coenzyme A (CoA) and re-esterified to triglycerides (TAGs, Figure 
4). These TAGs are further released into the circulation as part of very low-density 
lipoproteins (VLDL, Figure 4). As a result, there is an approximately 3-fold increase 
in circulating TAGs during late gestation (19). The circulating TAGs are also partly 
increased due to inhibition of adipose tissue lipoprotein lipase (LPL) as a result of 
insulin resistance and elevated estrogen concentrations (20). A positive correlation 
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between maternal TAG and newborn weight is reported (21). Circulating maternal 
total cholesterol is increased by 50% in late pregnancy, and is present mostly in low 
density lipoproteins (LDL) (19). A small increase in phospholipids is also observed 
(22). 6-10 weeks after delivery the gestational hyperlipidemia is essentially 
completely reversed to pre-pregnant levels (19). 
Figure 4: Maternal circulating lipid changes at the end of pregnancy. Modified from 
www.wikipedia.org 
1.1.4 Placental -oxidation, fatty acids and TAG biosynthesis 
De novo fatty acid biosynthesis is the metabolic pathway converting dietary 
carbohydrates to fatty acids for incorporation into various macromolecules, including 
membrane lipids and lipid storage in lipid droplets. Acetyl-CoA carboxylase  (ACC) 
and fatty acid synthase (FAS) are the principal enzymes required for de novo fatty 
acid biosynthesis (23;24). FAS is a large multifunctional enzyme complex, which 
converts acetyl-CoA and malonyl-CoA to fatty acids. ACC produces malonyl CoA, 
which is substrate for FAS. De novo fatty acid synthesis occurs primarily in the liver, 
with some activity in adipose tissue. These hepatic fatty acids are further exported as 
FFA
TAG 
(VLDL)
Chol
(LDL)
+
+
+
TAG
Liver
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Placenta
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VLDL to other organs through the circulation. In addition to the synthesis in liver and 
adipose tissue, endogenous fatty acid synthesis is observed in rapidly proliferating 
tissues such as the human placenta. Although little information is available on 
placenta de novo fatty acid synthesis, this information suggests that placenta has a 
high de novo fatty acid capacity. It has been reported that human placental fatty acid 
synthesis is more then 100-fold greater than that observed in cultured rat hepatocytes 
(25;26). These fatty acids can be further activated to acyl-CoA and thereafter 
esterified and stored as TAG in placenta. Both TAG synthesis and lipid droplets are 
reported in placental trophoblast cells (27;28). The fatty acids may also be 
transported directly to the fetus. Alternatively, the fatty acids may be used as energy 
for the placenta itself since high capacity for placental -oxidation is reported (29-
31). The importance of a functional -oxidation in fetal tissues is evident as fetal fatty 
acid oxidation (FAO) defects are potentially causes of maternal and fetal morbidity 
and mortality (32;33). Because the placenta is of fetal origin, the FAO defects are 
also present in the placenta. FAO defects of the fetus/placenta have recently been 
associated with hemolysis, elevated liver enzymes, and low platelet count (HELLP) 
syndrome, placental floor infarct and acute fatty liver of pregnancy (32;33). Several 
reports suggest that not only the fetus, but maybe rather the placenta may be involved 
in these maternal toxic effects of FAO defects. However, more research is needed for 
a definite clinical conclusion (30;34;35).  
1.1.5 Transport of lipids across the placenta 
The transport of a molecule from the maternal to the fetal circulation includes 
traversing the syncytiotrophoblast cell layer, connective tissue, and the fetal capillary 
endothelium. Every one of these layers can contribute to the transport properties of 
the placenta. In addition, the placenta is not merely a transport organ; placental 
metabolism itself also contributes to the net transfer of nutrients to the fetal side.  
Materno-fetal nutrient transfer across the placenta may proceed by different 
mechanisms, including facilitated diffusion, simple diffusion and active transport (2). 
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The proportion of transport across the placenta varies with the period of gestation and 
nutritional status of the mother.  
Most maternal fatty acids are transported as TAG in TAG-rich lipoprotein particles, 
Therefore these lipoproteins are important sources of fetal fatty acids and need to be 
transported to the fetus (36). TAG cannot directly cross the placental barrier. Thus, in 
order to accomplish this transport, an elaborate placental transport system has been 
developed. It includes LDL receptor (LDLR) and VLDL/apoprotein E receptors, 
placental LPL, placental phospholipase A2 and intracellular placental lipases (36-43). 
Alteration in placental LPL activity, and placental protein levels of LDLR and 
scavenger receptor (SR)-B1 were associated with intrauterine growth restriction 
(IUGR) (44-47). These alterations suggest a clinical importance of placental lipid 
transport for fetal growth.  
FFA and glycerol can cross the placental membrane by either diffusion or fatty acid 
binding/transport proteins. These proteins are involved in regulating the direction and 
amount of net flux of fatty acids across the placenta. CD36/fatty acid transporter is 
one such fatty acid transporter. It is a multifunctional transmembrane glycoprotein 
that is involved in long chain fatty acid uptake and is expressed in human primary 
trophoblast cells (48;49). Interestingly it also function as a class B scavenger receptor 
for oxidized LDL (oxLDL, (48;50-52)). 
1.1.6 Transport of cholesterol to the fetus 
Cholesterol is an important structural component of cellular membranes. It is also the 
precursor of steroid hormones, synthesized by the syncytiotrophoblasts. Maternal 
hypercholesterolemia correlate to the fatty streak formation in the fetal aorta (53), 
indicating the existence of materno-fetal cholesterol transfer. The ATP-binding 
cassette (ABC) cholesterol transporter proteins ABCA1 and ABCG1 are probably 
important for this trans-placental transport. Stefulj et al (54) recently demonstrated 
that inhibition of ATP-binding cassette (ABC) A1 and silencing of ABCG1 resulted 
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in approximately 60 to 70% reduction in cholesterol efflux from placental third 
trimester endothelial cells. Interestingly, both transporters were predominantly 
located in the apical membrane of placental endothelial cells. Both the SR-B1 and the 
oxLDL (lectin-like) receptor 1 and the lipoprotein receptor LDLR are also present in 
the placenta and could potentially contribute to the transfer of cholesterol from the 
maternal to the fetal side (55-57). Even if recent publications indicate a number of 
proteins involved in transport of cholesterol across the placenta, more studies are 
needed to clarify if placental cholesterol transfer is required to support the fetal needs 
and placental growth and biosynthesis of steroid hormones. 
1.1.7 Placental transfer and fetal needs for long chain 
polyunsaturated fatty acids 
Long chain polyunsaturated fatty acids (LCPUFA)s are of critical importance for the 
development of the fetus. Data from large cohort studies and randomized controlled 
trials highlight the importance of adequate amount of n-3 LCPUFAs for optimal 
cognitive and visual development and reducing the risk of preterm delivery (58-63). 
Docosahexaenoic acid (DHA, 22:6, n-3) is selectively accumulated in the retina and 
brain during development (64;65). Arachidonic acid (ARA, 20:4, n-6) serves as a 
precursor of bioactive eicosanoids and is reported to be associated with infant birth 
weight and preterm infant growth (66;67).  
The human body cannot introduce double bonds distal to the ninth carbon from the 
methyl end (- or n-end) of fatty acids. Thus, n-3 and n-6 poly unsaturated fatty acids 
(PUFA)s are essential fatty acids that must be obtained from the diet, either as 
linoleic acid (LA, 18:2 n-6) and -linolenic acid (ALA, 18:3 n-3), or their LCPUFA 
derivatives; ARA, eicosapentaenoic acid (EPA, 20:5, n-3) and DHA. If obtained as 
LA and ALA in the diet, the fatty acids must be elongated and desaturated to provide 
the biologically active LCPUFAs (Figure 5). Basal expression of delta 5 and delta 6 
desaturase and elongase has been detected both in placenta and fetal liver (68-70). 
However, their enzyme activities are low. Studies in baboons show that DHA from 
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the maternal diet is much more efficient than ALA as a source for fetal DHA 
accretion (71;72). Furthermore, supplementation of pregnant women with ALA does 
not result in higher umbilical cord blood levels of DHA (73). Taken together, the 
high needs of fetal LCPUFAs are difficult to meet by metabolism of their precursor 
PUFAs alone. Therefore, dietary intake of LCPUFAs and subsequent transport by the 
placenta to the fetus is important for optimal fetal development. 
 
 
 
 
 
 
 
 
Figure 5: LA and ALA elongation and desaturation to ARA and DHA respectively in 
placenta. Picture modified from www.wikipedia.org 
 
A number of studies have shown significantly higher ARA and DHA concentration in 
the fetal blood (the cord blood) compared to the maternal circulation, while LA and 
ALA concentrations were lower (22;74;75). This process, described as 
biomagnification, results in the preferential accumulation of DHA and ARA in the 
fetus during pregnancy. It represents an important mechanism to secure a sufficient 
supply of these critically important fatty acids to meet the increasing fetal demands. 
The transport of PUFAs across the placenta is selective in the order of preference, 
DHA > ARA > ALA > LA (76;77). Recently, the sophisticated use of 13C-DHA 
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demonstrated in vivo the preferred human placental transfer of DHA relative to LA, 
oleic acid (OA) and palmitic acid (78).  
1.1.8 Preferential uptake of LCPUFAs in placenta  
It has been reported that fatty acids can flip flop across membranes, but protein-
mediated transport is essential for the preferential transport of LCPUFAs (79). 
Placental transfer of LCPUFAs is probably a multi-step process involving both 
uptake and intracellular translocation. It is facilitated by several placental fatty acid 
uptake proteins, including CD36, fatty acid transport proteins (FATPs), fatty acid 
binding proteins (FABPs) and plasma membrane fatty acid binding protein 
(FABPpm) (Figure 6, reviewed in (80)). FABPpm is a peripheral membrane protein 
which, by binding to and increasing the concentration of fatty acids extracellulary, 
could contribute to placental transfer of fatty acids (81). The placenta-specific 
FABPpm (pFABPpm) resembles the ubiquitously expressed FABPpm, but is located 
exclusively on the maternal facing syncytiotrophoblast membranes and is involved in 
the preferential uptake of LCPUFAs in the placenta (Figure 6 (77;82;83)). FATP1 to 
4 and FATP6 are fatty acid transporters reported to be expressed in primary human 
term trophoblasts (84). The expression of particularly FATP1 and FATP4 could also 
be important for the materno-placental transport of LCPUFAs, as their placental 
expression were positively correlated to DHA levels in the placental phospholipid 
fraction (85). Once taken up by the cell, the fatty acids can be transported in the 
cytosol by FABPs. FABP1, 3, 4 and 5 are expressed in primary human trophoblast 
cells, and they are able to bind long chain fatty acids (48;86;87). Fatty acids can also 
be activated to acyl-CoA by acyl-co A synthetases and the activated protein can 
further be transported in the cytosol bound to acyl-CoA binding protein (ACBP, 
reviewed in (88-90). Several proteins containing acyl-CoA synthetase activity and 
ACBP are detected in placenta but further studies are needed to clarify their roles in 
placenta (84;91;92).  
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Figure 6: Proteins involved in lipid transport in placental trophoblast cells (modified from 
AK Duttaroy (80)) 
1.2 Preeclampsia 
1.2.1 Introduction to preeclampsia 
Preeclampsia is a pregnancy-specific syndrome, defined clinically as de novo 
hypertension and proteinuria occurring after 20 weeks of gestation. In Norway it 
affects 3.7% of all pregnancies, and is a leading cause of maternal death (93;94). 
World-wide preeclampsia is the cause of 50.000 maternal deaths annually (95). The 
severe forms of preeclampsia typically results in preterm delivery, low-birth weight 
and increased risk of fetal morbidity and mortality (96).  
The definition of preeclampsia has been debated, and there is no global consensus. 
According to the National High Blood Pressures Education Program Working Group 
and High Blood Pressure in Pregnancy the following criteria for diagnosis of 
preeclampsia is recommended (97). These criteria have also been used to define the 
preeclamptic patient group in this thesis: 
CD36
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pFABPpm Maternal side
Fetal side
FABP
FABPpm
FATP
CD36
FFA C>14
FFA
DHA/ARA
FABPpm
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1) "Blood pressure at 140 mm Hg systolic or higher or 90 mm Hg diastolic or higher 
that occurs after 20 weeks of gestation in a woman with previously normal blood 
pressure". 
 2) "Proteinuria, defined as urinary excretion of 0.3g protein or higher in a 24 hour 
urine specimen (or protein dipstick reading equal to or higher than 1+ on more than 
one midstream urine sample six hours apart)". 
When pre-existing hypertension is present in the women, preeclampsia is defined as 
superimposed on the chronic hypertension. Eclampsia is an end stage of the disease 
involving the occurrence of seizures in a preeclamptic woman, where the seizures 
cannot be attributed to other causes. The HELLP syndrome is a variant of 
preeclampsia (98). 
Preeclampsia is unpredictable in its onset, progression and severity. It is sometimes 
divided into severe, early onset preeclampsia occurring prior to week 34 of gestation, 
and a mild, late onset preeclampsia occurring at or after 34 weeks of gestation 
(99;100).  
Despite decades of research on the etiology and mechanism of preeclampsia, the 
pathogenesis is not fully understood, but increasing evidence support the concept that 
it is a multifactorial syndrome involving both the mother and the fetus. The 
pathogenesis is generally recognized to include an abnormal placental implantation 
and endothelial dysfunction resulting from oxidative stress and excessive 
inflammatory response, but numerous other factors are also suggested to be involved 
(reviewed in (6;101) ). Several lines of evidence point to a key role of the placenta in 
the aetiology of the disease as delivery resolves the syndrome, it occurs without the 
presence of a fetus (in molar pregnancies) and the risk of preeclampsia is increased 
by greater placental mass (102). 
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1.2.2 Hyperlipidemia in preeclampsia 
Hyperlipidemia of pregnancy develops in every pregnant woman, but is significantly 
increased in women with preeclampsia relative to healthy pregnancies. The lipid 
abnormalities of preeclampsia include hypertriglyceridemia, increased circulating 
FFAs, reduced high density lipoproteins (HDL) and increased concentrations of small 
LDL which leads to the presence of oxLDL in maternal circulation (103-108), while 
total and LDL cholesterol levels are not substantially different (104;105). This 
exaggerated lipid adaptation of preeclamptic pregnancy is strikingly similar to 
abnormalities associated with cardiovascular disease (109-112). Indeed, preeclampsia 
is related to an increased risk of developing cardiovascular disease later in life 
(systematically reviewed in (113)). The two disease entities also have several risk 
factors in common including obesity, diabetes mellitus, insulin resistance and lipid 
abnormalities (111;114). Both cardiovascular disease and preeclampsia include 
presence of endothelial dysfunction, partly due to increased lipid peroxidation. 
“Acute atherosis” of the decidual/uterine spiral arteries in preeclampsia closely 
resembles the early stages of atherosclerotic lesions found in cardiovascular disease 
(115). In addition, recent research indicates increased risk of cardiovascular disease 
in the offspring of preeclamptic mothers, but whether this is attributed to genetic or 
epigenetic factors or only an adverse pro-atherogenic lipid profile in utero is not clear 
(reviewed in (116)).  
A rise in circulating TAG is also shown to be present prior to clinical onset of 
preeclampsia (117), as early as 10 weeks of gestation (118). There seems to be a 
dose-response effect, with a four-fold higher adjusted risk of developing 
preeclampsia in women with the highest circulating levels of TAG compared to 
normal TAG levels (108). Although hypertriglyceridemia may contribute to the 
development of preeclampsia, therapeutic intervention is probably not a good 
alternative, as severe correction of maternal hypertriglyceridemia in rodents has been 
shown to mediate negative effects on fetal growth and development (119). 
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1.3 Long chain acyl-CoA synthetases 
The activation of free fatty acids by the addition of a CoASH group is essential for 
the participation of fatty acids in most metabolic reactions, including -oxidation, 
biosynthesis pathways and phospholipid remodelling. Acyl-CoA synthetases have 
been found in all organisms investigated, testifying to the evolutionary conservation 
and essential role of this activity (89). The activation is a two-step reaction where the 
first step is the biosynthesis of an acyl-AMP intermediate from fatty acid and ATP, 
and the second step is the exchange of AMP with CoASH to produce the activated 
acyl-CoA:  
Fatty acid + ATP + Mg2+  Acyl-AMP + Mg2+ + PPi 
Acyl-AMP + CoASH  Acyl-CoA + AMP 
All proteins containing acyl-CoA synthetase activity have two conserved amino acid 
(aa) sequence domains: a 10 aa, highly conserved AMP-binding domain and a 35 aa 
domain originally proposed to be important for fatty acid-binding properties 
(120;121). Later it has been found that the fatty acid binding is located between these 
two domains (122). 
The family of acyl-CoA synthetases can be divided into five sub-families based on 
fatty acid chain length preference; acyl-CoA synthetase short-chain (C2 to C4), 
medium chain (C4 to C12), long chain (ACSL, C12 to C20), bubblegum (ACSBG, 
C14 to C24) and very long chain (FATP, C18 to C26) (reviewed in (89;123)). Thus, 
there are three related families of proteins able to activate long chain fatty acids, 
ACSL, ACSBG and FATP (124-129).  
The ACSBG1 and ACSBG2 were only recently discovered and little information is 
available on their function (129;130). Both ACSBGs have acyl-CoA synthetase 
activity with preference for long chain fatty acids more than very long chain fatty 
acids, and expression restricted to brain, ovary and testis (128-131).  
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The FATPs are the most thoroughly investigated of the long chain and very long 
chain acyl-CoA synthetase families. Six members of the FATP family are known, 
FATP1 to FATP6, which differ in their tissue expression, subcellular localizations 
and substrate specificities (132-137). They are documented to have intrinsic acyl-
CoA synthetase activity and to increase uptake of fatty acids when overexpressed. 
Thus, it has been an ongoing controversy as to whether they are fatty acid 
transporters, acyl-CoA synthetases or both (reviewed in (90;138)). Studies on FATP4 
have debated whether plasma membrane location is necessary for cellular fatty acid 
uptake. Despite the exclusive localisation to endoplasmic reticulum, FATP4 over-
expression significantly increased the cellular uptake of fatty acids in one study, but 
not in another study (139;140). Mutated FATP4, containing a non-functional acyl-
CoA synthetase domain, did not increase the uptake of fatty acid when 
overexpressed, in contrast to wt FATP4, indicating that the acyl-CoA synthetase 
function could be necessary for the fatty acid uptake (140). Evidence for a role of 
acyl-CoA synthetase in uptake of fatty acids is supported by the fact that the acyl-
CoA synthetase inhibitor Triacsin C strongly reduces the fatty acid uptake (141). Co-
immunoprecipitation of ACSL1 and FATP1 in adipocytes further suggests that acyl-
CoA synthetase is important for fatty acid uptake (141). On the other hand murine 
FATPs transfected into FATP mutated yeast strains did not show correlation between 
acyl-CoA synthetase activity and long chain fatty acid uptake (142). Furthermore, 
FATP3 was found to have acyl-CoA synthetase activity without increasing fatty acid 
uptake (134). It appears that acyl-CoA synthetase in certain situations is necessary for 
fatty acid uptake, but is alone not sufficient to ensure fatty acid uptake. Thus, clearly 
more studies are needed for a definitive conclusion on the role of acyl-CoA 
synthetase activity on fatty acid uptake.  
Five genes in the ACSL family have been identified based on sequence homology 
(143;144). They are named ACSL1 and ACSL3 to 6 and differ in their tissue 
distribution, intracellular locations and regulation, suggesting distinct functions 
(143;145;146). The ACSL family can be further divided into two subfamilies where 
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the ACSL1, 5 and 6 constitute one subfamily and ACSL3 and 4 constitute another 
subfamily (143). Coleman et al have suggested that instead of being redundant, the 
different ACSLs channel fatty acids into distinct metabolic pathways (147). ACSL5 
was initially thought to be involved in -oxidation (148), but has later also been 
shown to increase TAG biosynthesis in hepatoma cells (149). Overexpression studies 
reveal that ACSL6 in the brain is important for uptake and incorporation of DHA and 
ARA into phospholipids, but not TAG (150;151). Although increasing evidence 
supports the hypothesis, many questions regarding the "channelling hypothesis" still 
remain to be answered, including the subcellular localization of the different ACSLs 
in different cells and environments, which could be important for the channelling 
mechanism (89).  
Besides activation of fatty acids, a function similar to that reported on FATPs in the 
transport of fatty acids has been indicated for members of the ACSL family. 
Expression of mammalian ACSL1, ACSL4 and ACSL6 in yeast cells lacking native 
long-chain acyl-CoA activity leads to enhanced fatty acid uptake (146). 
Overexpression of ACSL5 and ACSL6 in rat hepatoma cells and neuronal cells 
respectively increased the uptake of fatty acids in these cells (149;150). The 
hypothesis is that FFAs cross the plasma membrane, where it is esterified to the acyl-
CoA product that is no longer lipid permeable and thus is trapped inside the cell. 
Interestingly, Lobo et al (152) recently showed that ACSL1 was involved in fatty 
acid efflux rather then uptake in an adipocyte cell line, opening the possibility for a 
novel role of the ACSLs. 
ACSL3 was cloned from rat brain in 1996 and in human placenta the year after. It 
was shown to have substrate preference in the order of myristic acid (14:0): ARA : 
EPA > OA >> DHA (92;124). The ACSL3 is highly expressed in prostate, skeletal 
muscle, testis, heart and placenta (153). It consist of 17 exons, spanning a domain of 
more than 80 kb (153). A difference in translation start gives rise to two different 
ACSL3 isoforms with similar cellular and tissue localization (154). ACSL3 is one of 
the most abundant proteins associated with lipid droplets in huh7 hepatocytes, but it 
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was also found in the endoplasmatic reticulum and plasma membrane fraction in 
these cells (155;156). ACSL3 was associated with the biosynthesis of neutral lipids in 
Huh7 cells in one study (156). In another study in 3T3-L1 adipocytes ACSL3 was 
detected on lipid droplets only during lipolysis (157). Hence, the role of ACSL3 in 
channelling fatty acids to anabolic compared to catabolic pathways needs more 
investigation. 
1.4 Nuclear Receptors 
It took the scientific world approximately 10 years from the human genome 
sequencing project was initiated until the entire human genome was sequenced, and it 
was found to consist of 20.000-25.000 protein coding genes (158). The same genetic 
material is present in almost all cells of the body, and the variability among cells and 
tissues depend on the regulation of these genes. The importance of an accurate 
transcriptional control is emphasized by the fact that almost 10% of all human genes 
are estimated to be transcription factors (159). Hence, transcription factors constitute 
the single largest family of human genes. The comprehension of this transcriptional 
regulation is fundamental for the molecular understanding of human biology in health 
and disease  
The Nuclear receptor (NR) superfamily is a diverse group of evolutionary related 
DNA binding transcription factors of which 48 are identified in humans (reviewed in 
(160)). Many of these NRs are ligand dependent transcription factors, but a 
significant number are still considered as orphan receptors, since no physiological 
relevant ligand has yet been identified (161;162). Their ligands are hydrophobic and 
small size, but except from these common features, they consist of a great variety of 
molecules. They include several fatty acids, cholesterol derivatives (steroid 
hormones, vitamin D, bile acids, oxysterols and other cholesterol metabolites), 
retinoids, thyroid hormone, prostaglandins, leukotriens, and xenobiotics (163). The 
ligand-dependent property permits NR to serve essential functions as communicators 
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between the intracellular or body environment and the genome. They play critical 
roles in a variety of biological processes including development, reproduction, 
homeostasis, inflammation, and metabolism, by altering target-gene expression 
(161;163;164).  
1.4.1 Subfamilies of the NRs 
The NRs can be divided into subfamilies in many different ways, based on properties 
such as phylogenetic analysis of sequence homology, ligand sources and 
physiological functions (160;165). A classical way of dividing the NRs is according 
to DNA-binding and dimerization properties, as presented in table 1 (162). This 
classification divides the NRs into four groups (Table 1). Class 1 receptors include 
the classical steroid hormone receptors, which bind to regulatory sequences on DNA 
as homodimers. Class 2 receptors are heterodimers with RXR and function in a 
ligand-dependent manner. Examples of these receptors include several NRs that are 
known to regulate lipid biosynthesis, flux, storage and utilization, of which some of 
the most important are the peroxisome proliferator-activated receptors (PPAR)s and 
the liver X receptor (LXR)s. The next two classes contain orphan nuclear receptors, 
which are so named because their ligands were unknown, at least at the time when the 
receptor was identified. Class 3 are orphan receptors, which function as homodimers, 
and class 4 are orphan receptors, which function as monomers.  
Recently the crystallization of the first full-length NR pair, PPAR and RXR was 
identified after many years of effort. It showed that the PPAR ligand binding domain 
(LBD) dominates the entire RXR molecule and seems to play the major role of the 
two (166). 
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Steroid Receptors  RXR heterodimers 
NR agonist  NR agonist 
GR glucocorticoid  LXR oxysterols 
MR mineralocorticoid  PPARa 
PR progesterone  PPARg 
fatty acids/ 
15d-delta12,14-PGJ2 
AR androgen  FXR bile acids 
ER estrogen  PXR/SXR xenobiotics 
   T3R tyroid hormone 
   RAR all-trans RA 
   VDR 1,25-(OH)2-VD 
   CAR androstane 
   EcR ecdysone 
     
Dimeric Orphan Receptors  Monomeric/Tethered Orphan Receptors 
RXR 9-cis RA  NGFI-B  
COUP   SF-1  
HNF-4   Rev-erb  
TR2   ROR  
TLX   ERR  
GCNF     
     
  
Table 1: The nuclear receptor superfamily. The table shows the subdivision of NRs into four 
classes according to their DNA-binding and dimerization properties (162). 
1.4.2 Structure of the NRs 
NRs share a characteristic structure that consists of five to six homologousdomains 
(Figure 7, reviewed in (160;163)). The amino-terminal domain (often referred to as 
the A/B domain or the modulator domain) does highly vary in sequence between 
different NRs. This domain is structurally flexible and contains surfaces for both 
activation and repression of gene transcription (reviewed in (167)). The A/B domain 
usually contains a transcriptional activation functional domain, termed activation 
function 1 (AF-1). The AF-1 domain may be involved in cofactor interaction, and it 
is the target of post-translational modifications (168). Next to the A/B domain is the 
C domain also called the DNA-binding domain (DBD). It is a highly conserved 
domain containing two zinc fingers, which bind to specific sequences of DNA called 
hormone response elements (HRE)s. These HREs consist of one or two consensus 
core half sites in the promoter or enhancer region of the target genes, but the exact 
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HRE nucleotide sequence in each target gene can differ considerably from the 
consensus sequence (169). The HRE of dimeric NRs are organized as direct (DR), 
inverted (IR) or everted repeats (ER) of a six-nucleotide half site DNA consensus 
sequence. The D region serves as a hinge between the DBD and the E domain, which 
is also called the ligand-binding domain (LBD) This flexibility permits the DBD and 
the LBD to adopt different conformations. The LBD is located in the carboxy-
terminaly part of the protein, which is the hallmark of NRs. Within this C-terminal 
domain is another AF domain, which is termed AF-2 (Figure 7, reviewed in (170)). 
The AF-2 is important for the NR LBD to activate gene transcription and it mediates 
ligand dependent transactivation and cofactor recruitment. 
 
 
 
 
 
Figure 7: The protein structure of NRs. The NRs share a characteristic structure that 
consists of five to six homologous domains. Modified from www.wikipedia.org 
1.4.3 NR cofactors 
In addition to site-specific DNA binding and binding of ligand, the NR 
transcriptional activity depends on interaction with coactivators and corepressors. 
More than 300 NR coregulators have been characterized, and they can broadly be 
divided into coactivators that increase transcription and corepressors which silence 
gene expression (reviewed in (171;172)). The coactivators are recruited upon NR 
ligand binding due to a conformational change in the LBD of the receptor. Most 
coactivator complexes stimulate transcription through direct interaction with the basal 
transcription machinery or by inducing histone protein modifications that enhances 
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the access to the DNA (172). Some unliganded nuclear receptors are bound to DNA 
in association with corepressors, repressing transcription of target genes. Examples of 
such corepressors are nuclear receptor corepressor (NCoR) and silencing mediator of 
retinoic acid (SMRT, (173)). Upon NR ligand binding, conformation changes in the 
NR LBD releases the corepressors in an active mechanism clearing the corepressors 
from the NRs and recruiting the coactivators.  
In addition to ligand and cofactor binding the NRs are reported to be modified in 
many other ways such as by; phosphorylation, glycosylation, methylation, 
acetylation, ubiquitinylation and small ubiquitin-like modifier (SUMO)ylation (172). 
1.4.4 RXRs and PPARs 
The RXRs consist of three members RXR,  and  ((174-176)). They can form 
transcriptionally active homodimers on DR-1 elements, but are also the heterodimeric 
partner of many NRs (177;178). The RXR are activated by the endogenous agonist 9-
cis retinoic acid and several synthetic agonists (179-181).  
The PPARs consist of three distinct members, PPAR,  and  (182-184). The array 
of genes regulated by each PPAR is divergent, and include genes involved in cellular 
differentiation, development and metabolism (185). The PPARs are important 
regulators of lipid metabolism. PPAR and PPAR predominantly enhance energy 
expenditure in metabolic tissues, and PPAR promotes lipid storage (186). The 
PPARs heterodimerize with RXRs and preferentially bind to DR-1 elements. PPAR 
and PPAR are the molecular targets of a number of marketed drugs. Fibrates are 
PPAR activators and used in humans as a class of hypolipidemic drugs (187). The 
thiazolidinediones are selective PPAR agonists used in humans to increase insulin 
sensitivity (188). Fatty acids and eicosanoids have also been identified as natural 
ligands for the PPARs (186).  
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1.5 LXRs 
The LXRs were cloned in 1994-1995 (189-194). Subsequently until today, more than 
1200 publications have established a role for the LXRs in cholesterol homoeostasis, 
lipogenesis, glucose metabolism, atherosclerosis, diabetes, Alzheimer's disease, 
dermatitis, immunology, and inflammation (195-199). The LXR subfamily of NRs 
consists of two members; LXR (NR1H3) and LXR (NR1H2), which share 
considerable sequence homology and are activated by the same agonists (200). LXR 
is ubiquitously expressed, whereas LXR has a more restricted expression pattern 
predominantly in tissues known to be important in lipid metabolism 
(189;193;194;201).  
 
 
 
 
 
 
 
 
 
 
Figure 8: Binding of RXR/LXR heterodimer to LXRE with and without activators 
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Both LXRs form heterodimers with RXR, and the heterodimer bind to LXR 
responsive elements (LXREs) in the promoter of the target genes (202). The LXREs 
are classified as DR-4 elements because they consist of two direct repeat hexamers 
separated by four nucleotides (189;193). In the absence of ligands, the heterodimer 
functions as an inhibitor bound to the LXRE, together with corepressor complexes. 
Upon ligand binding, a conformational change of the protein complex induces the 
release of corepressors and the recruitment of coactivators resulting in transcription 
of the target genes (Figure 8 (203;204)).  
1.5.1 LXR ligands 
A major breakthrough in the understanding of LXR was the identification of 
oxysterols as endogenous LXR agonists (205;206). Oxysterols are oxidized 
derivatives of cholesterol and are present for example in oxLDL (207). Some of the 
most potent of these endogenous LXR activators are 22(R)-hydroxycholesterol, 
20(S)-hydroxycholesterol, 24(S), 25-epoxycholesterol, and 27-hydroxycholesterol 
(200;205;206). In addition LXR can be activated by non-steroidal synthetic agonists, 
of which T0901317 and GW3965 are the most commonly used (208;209).  
LXR activation by synthetic agonists leads to reverse cholesterol transport (returning 
of peripheral cholesterol to the liver) resulting in decreased atherosclerosis (210). 
Despite this promising effect by these agonists on atherosclerosis, the undesirable 
side effects of increased hepatic lipogenesis leading to liver steatosis and 
hypertriglyceridemia has made it unlikely that this first generation of LXR ligands 
will be used therapeutically (209). Still, these synthetic LXR agonists have been 
valuable tools for the identification and characterization of LXR target genes and the 
understanding of LXR regulated physiological processes. Along this line, there is an 
ongoing search for tissue selective agonists or agonists selective for only one of the 
LXRs (reviewed in (211)). An ideal agonist would have preserved the beneficial 
effects of inducing ABCA1 transporters in macrophages and liver, without the sterol 
regulatory element binding protein (SREBP)-1 regulatory effects leading to 
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hypertriglyceridemia and liver steatosis (212). Recently, the first human trial of an 
LXR agonist on healthy subjects was performed, but many side effects, mainly in the 
central nervous system were observed (213). 
In vivo studies with either LXR-/- or LXR -/- mice indicate a more prominent role of 
LXR than LXR in controlling hepatic lipogenesis. Hence, selective LXR agonists 
are candidates for such beneficial effects and several LXR agonists have been tested 
(214). Still, the question remains to be answered whether the activation of LXR 
alone is sufficient to ameliorate the atherosclerosis process.  
In contrast to many oxysterol and synthetic LXR agonists that activate LXR, several 
compounds with antagonising properties have been reported, including PUFAs. 
These fatty acids inhibit LXR activation by competing with LXR agonist binding in 
the order of ARA > EPA > DHA > ALA, whereas saturated and monounsaturated 
fatty acids have very little effect on LXR activation in Human Embryonic Kidney 
293 cells (215).  
1.5.2 LXR in cholesterol homeostasis 
The LXRs were initially described as regulators of cholesterol metabolism through 
the identification of the first LXR target gene, cholesterol 7 alpha-hydroxylase, in 
rodent liver, which is the rate-limiting enzyme in conversion of cholesterol into bile 
acids (200). Later, numerous studies have established the LXRs as cholesterol sensors 
that regulate both cellular and systemic cholesterol homeostasis in a tissue-specific 
manner. In the liver, LXR regulates genes leading to increased biliary cholesterol 
excretion (216). In peripheral tissues like macrophages, the LXRs control the 
expression of genes involved in reverse cholesterol transport (217-222). Recently, a 
new regulatory pathway of LXR in cholesterol homeostasis was reported by Zelcer et 
al (223). LXR was shown to increase the expression of the gene inducible degrader of 
the LDLR (Idol), which subsequently target LDLR for degradation, resulting in a 
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suppression of LDL uptake in a number of tissues. Taken together, the systemic 
activation of LXRs leads to net cholesterol excretion and reduced atherosclerosis.  
1.5.3 LXR in lipogenesis 
Analysis of mice deficient in LXR and LXR reveal the involvement of the LXRs in 
fatty acid biosynthesis (lipogenesis) and secretion of TAG in the liver (224). These 
mice were deficient in hepatic expression of a number of lipogenic genes including 
SREBP-1, stearoyl-CoA desaturase (SCD)-1, FAS and ACC. Accordingly, 
administration of LXR agonist to wild-type mice induced the expression of these 
lipogenic genes and results in elevated plasma and hepatic triglyceride levels (209). 
LXR activation was also shown to increase expression of SREBP-1 and FAS and 
give lipid accumulation in cultured adipocytes (225). The effect of LXRs on 
lipogenesis is largely due to the direct LXR-mediated induction of the transcription 
factor SREBP-1c, which subsequently upregulates FAS, SCD-1 and ACC. SREBP-
1c is a master regulator of genes involved in fatty acid biosynthesis, through the 
binding to SREBP responsive elements in the promoter of target genes (reviewed in 
(226)). However, the treatment of SREBP-1c-/- animals with LXR agonist indicates 
the ability of LXR to induce the expression of some lipogenic genes independently of 
SREBP-1c (227). Furthermore, the recognition of the known SREBP-1c target genes 
FAS, SCD-1 and ACC as direct LXR target genes supports this observation. 
Peroxisome proliferator activated receptor (PPAR), Carbohydrate responsive 
element-binding protein (ChREBP), LPL, Angiopoietin-like 3 and CD36 are also 
direct LXR target genes involved in lipid metabolism (228-232). Hence, systemic 
activation of LXR induces a whole collection of genes involved in lipid metabolism, 
with the net effect of increasing hepatic lipogenesis, circulating TAG and hepatic 
steatosis.  
In addition to hepatic de novo fatty acid biosynthesis, circulating FFAs are also a 
source of hepatic lipids. LPL is an important enzyme in lipid metabolism hydrolyzing 
TAG in circulating lipoproteins to release FFA to muscle, adipose tissue, and 
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macrophages. The direct LXR-mediated regulation of LPL is shown in several tissues 
to increase fatty acid uptake and further TAG biosynthesis and lipid accumulation 
(233). The involvement of LXR in lipid uptake is further demonstrated by the recent 
identification of CD36 as a direct LXR target gene in liver (234). CD36 is an 
important gene in lipid homeostasis, and is tightly controlled by a number of NRs. In 
addition to the regulation by LXR, CD36 is shown to be a direct pregnane X receptor 
(PXR) and PPAR target gene, and an additive increase in CD36 expression is 
observed with both PXR and LXR agonist together in liver (234). Not only is CD36 
regulated by a number of NRs, but the NRs themselves are also reported to regulate 
each other in different tissues, which again could potentially influence the regulation 
of CD36. PPAR is induced by PXR activation in liver, and PPAR is a direct target 
gene for LXR in adipocytes (234;235). Furthermore, LXR is a target gene for PPAR 
in macrophages and adipocytes (225;236). Such a complex regulation of genes in the 
lipid metabolism including a whole network of transcription factors is not unique to 
CD36 (229;237-240). It permits the fine-tuning of mRNA concentrations of 
important metabolic genes to meet the shifting metabolic needs of the body, by 
integrating the information from nutritional, hormonal and cell signalling.  
1.5.4 LXR, glucose, insulin and diabetes mellitus 
Increasing evidence has placed LXR as regulator of glucose homeostasis and insulin 
action. LXR agonists improve glucose tolerance in diabetic rodent models mainly 
through hepatic LXR (241). In liver, LXR activation represses phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase expression, whereas in adipose tissue, 
LXR mediate direct upregulation of glucose transporter 4 (199;242;243). 
Furthermore, high concentrations of glucose was shown to bind and activate LXR, 
although these findings have been debated (244;245). Tobin et al (246) show that 
hepatic LXR is involved in insulin regulation of both cholesterol homeostasis and 
triglyceride metabolism in liver as insulin increases the expression of hepatic LXR 
and LXR target genes. Finally, LXR was shown to increase glucose dependent 
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insulin secretion in pancreatic -cells (247). However, LXR-mediated activation does 
not always lead to increased insulin-sensitivity. Activation of LXRs increase TAG 
accumulation in human skeletal muscle and pancreatic -cells, and increase 
pancreatic -cell apoptosis, conditions usually associated with insulin resistance and 
type 2 diabetes mellitus (247-249). Thus, even if several studies support a beneficial 
role of LXR activation, further studies are needed to clarify the net effect of LXR 
agonists on type 2 diabetes mellitus. 
1.6 PPARs and RXRs in placenta 
Of the NRs involved in lipid metabolism, most research in placenta has been done on 
the PPARs and the RXRs. As RXR is a heterodimeric partner of both LXR and 
PPAR, and numberous studies show the cross talk between PPARs and LXRs, the 
regulation of these NRs in placenta could be relevant for the understanding of LXRs 
in placenta. An overview of the literature on RXRs and PPARs in placenta is given in 
this thesis introduction, Also, the role of LXR in placenta and other reproductive 
organs will be addressed, but limited information is available on LXR in placenta. 
All three PPARs and two RXRs (RXR and RXR) were detected in human and rat 
placenta and placental trophoblast cells, while RXR was only detected in rat 
placenta (250). Both PPARs and RXRs have been reported to be involved in several 
aspects of pregnancy development including implantation, placentation, trophoblast 
invasion and fatty acid uptake (reviewed in (251)).  
Studies of PPAR -/- mice revealed abnormal placental development resulting in 
embryonic death at mid gestation (252). Detailed analysis of these mice revealed that 
the PPAR/RXR heterodimers are essential for differentiation of trophoblast cells and 
the formation of a functional placenta (252). Both PPAR and RXR agonists also 
increase differentiation of human primary cytotrophoblast (253). Increased hCG 
production is a hallmark for cytotrophoblast differentiation, and this reproductive 
hormone was also increased by PPAR, and shown to be a direct PPAR target gene 
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(253;254). Even though several PPAR target genes have been identified in placenta, 
this cannot fully explain the lethal phenotype observed in PPAR -/- mice (255;256). 
Hence, there is a continuous research going on to decipher the gene regulation 
responsible for this PPAR -/- phenotype (251) 
A role for PPAR in trophoblast invasion has also been demonstrated. Both synthetic 
and natural PPAR agonists were shown to inhibit extravillous cytotrophoblast cell 
invasion in in vitro invasion assays (257;258).  
PPAR is involved in differentiation, fatty acid transport and accumulation in 
adipocytes (259). Likewise, PPAR seems to play a role in fatty acid uptake and 
accumulation in placenta. PPAR -/- and RXR -/- mice both lack lipid droplets 
normally present in wt mice, and PPAR and RXR agonist increase fatty acid uptake 
and accumulation in primary human trophoblasts (84;252;260;261). In line with these 
observations, both the fatty acid transporters FATP1 and FATP4, and the lipid 
droplet protein adipophilin are upregulated by PPAR activation in human 
trophoblast cells (84;262).  
An essential role for PPAR in placental development has been demonstrated in 
implantation and trophoblast differentiation. PPAR -/- mice develop placental 
abnormalities, with compromised size of trophoblast giant cell and increased 
embryonic lethality (263). In line with this observation, PPAR was later shown to be 
crucial for giant cell differentiation in vitro (264). PPAR regulate the production of 
cyclooxygenase (COX)-2 derived prostacyclin I2 (PGI2), and COX-2 -/- female mice 
display decreased fertility, partly due to impaired blastocyst implantation and 
decidualization (265;266). Treatment of these mice with PPAR selective agonist 
restored the implantation (266). PPAR was also shown to be essential for the effect 
of PGI2 to enhance mouse blastocyst invasion (267;268).  
PPAR activation is reported to inhibit secretion of hCG and increase secretion of 
progesterone from immortalized human extravillous trophoblast cells (269). PPAR -
/- mice had increased abortion rate, which was further increased in diabetic PPAR -/- 
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mice (270). The increased abortion rate was suggested to involve a compromised 
materno-fetal lipid exchange, but no placental abnormalities were observed. Hence, 
further studies are needed to clarify the role of PPAR in embryonic development.  
RXR is the main RXR isoform expressed in the placenta (250). As the PPARs 
heterodimerize with RXR and both PPAR and PPAR are essential for placental 
development it would be expected that RXR -/- mice display a similar abnormal 
placental development. As expected RXR -/- mice die in utero from day E12.5 to 
E16.5 and exhibit a similar placental phenotype as PPAR (260;271). The RXR -/-
/RXR -/- mice exhibited a much more severe phenotype resembling both PPAR -/- 
and PPAR -/- mice, indicating that RXR to some degree could compensate for the 
loss of RXR (272).  
1.7 LXR in reproductive tissues 
The major part of research on LXRs has focused on their role in liver and 
macrophages. However, recent studies indicate putative roles for LXRs in many other 
tissues including placenta and other reproductive tissues. Both male and female 
LXR -/-, LXR -/- and LXR -/-/ -/- mice are less fertile then their wild type (wt) 
controls (273-276). Male LXR -/- mice were essentially infertile by 5 months of age, 
while male LXR -/- mice had reduced testicular testosterone and higher apoptotic 
rate of germ cells, indicating that LXR and LXR collaborate to maintain both 
integrity and function of the testis (273). It appears that LXR regulation of cholesterol 
homeostasis during the maturation of sperm cells is crucial for male fertility 
(273;274;276). In female LXR -/-/ -/- mice, oocyte maturation is impaired due to a 
reduced effect of follicle-stimulating hormone, while LXR agonist stimulates 
resumption of meiosis in isolated oocytes (275). Further, female LXR -/-/ -/- mice 
were recently identified to have many of the same features of complications as 
animals with ovarian hyperstimulation syndrome, which is a common complication 
of fertility treatment when inducing ovulation (277). The complications included 
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enlarged ovaries with increased vascularity, and elevated circulating estradiol. 
Isolated uteri from LXR -/- mice had reduced contractile response to oxytocin, 
probably due to an abnormal increase in cholesterol content, indicating a role in 
uterine contraction during labour (278).  
A function for LXR in placental cells was first described by Pavan et al in 2004 
(279). They showed that oxLDL inhibited cultured extravillous cytotrophoblast 
invasion in vitro. Only oxLDL containing a high amount of oxysterols contained 
these properties. These results were confirmed with a synthetic LXR agonist, 
suggesting that LXR activation could interfere with implantation. Later the 
identification of endoglin as a direct LXR agonist in JAR cells further suggest 
inhibitory activity of LXRs in trophoblast invasion (280). Endoglin is an 
antiangiogenic protein and an inhibitor of trophoblast invasion, with increased 
maternal circulating levels in preeclampsia (281).  
Several recent publications have investigated the role of LXR on cholesterol transport 
in the placenta. Stefulj et al (54) showed that isolated endothelial cells from human 
term placenta had a 2.5-fold higher cholesterol release to apoprotein A-I and 
increased cholesterol efflux following LXR activation, as compared to human 
umbilical vein endothelial cells. Fetuses with Smith-Lemli-Opitz syndrome are 
incapable of de novo cholesterol biosynthesis (282). In utero treatment of a Smith-
Lemli-Opitz syndrome mouse model with LXR agonist resulted in increased 
cholesterol content, probably due to increased expression of Abca1 (57). This opens 
for the possibility that activation of LXR in utero could attenuate the irreversible 
congenital malformations present in Smith-Lemli-Opitz syndrome patients already at 
birth.  
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2. Aims of the study 
At the start of this thesis, very little information was available on the role of LXR in 
placenta. The importance of LXR in lipid homeostasis in other tissues prompted us to 
explore the transcriptional activity and physiological roles of LXR and LXR in 
placental lipid transport and metabolism. This knowledge could be important in order 
to increase the understanding of molecular mechanisms involved in pathological 
pregnancies associated with hyperlipidemia. 
The following projects were addressed in Paper I, II and III:  
1. Gene expression of LXRs in human trophoblast cell lines and placental tissue 
2. The role of LXR and LXR in lipid metabolism and other functions in placental 
trophoblast cells 
 Are the LXRs involved in de novo fatty acid biosynthesis in trophoblasts? 
 Are the LXRs involved in activation of fatty acids in trophoblasts? 
 Are the LXRs involved in fatty acid uptake by trophoblasts? 
 Are the LXRs involved in regulation of hCG expression and secretion in 
 trophoblasts? 
3. The search for new LXR target genes in human placental trophoblast cells.  
During the work of this thesis, we observed increased expression of ACSL3 on 
microarray in human primary trophoblast cells treated with LXR agonist. Based on 
this finding the following additional questions were addressed: 
 Is ACSL3 a direct LXR target gene in trophoblasts? 
 Is ACSL3 involved in  LXR-mediated fatty acid activation and uptake in 
 trophoblasts? 
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4. The expression of LXR and LXR in relation to changes in physiological lipid 
parameters, in placental tissue in preeclampsia 
 Is LXR, LXR and LXR target genes differentially expressed in 
 preeclamptic placentas compared to controls? 
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3. Summary of papers 
3.1 Paper I: 
Liver X receptors mediate inhibition of hCG secretion in a human placental 
trophoblast cell line 
In the first paper, we investigated whether LXR has similar lipid metabolic effects in 
placental trophoblast BeWo cells as observed in liver and adipose tissues. We further 
investigated the  LXR-mediated regulation of hCG secretion from BeWo cells.  
We identified the expression of LXRs in placenta trophoblastic BeWo and JAR cells. 
We further indirectly identified the presence of functional LXR protein, by induced 
expression of a minimal LXRE containing promoter when stimulating with LXR 
agonist.  
Next, we investigated the effects of LXR activation on de novo fatty acid synthesis 
and further metabolism into complex lipids. We observed increased biosynthesis of 
all classes of lipids investigated (FFA, PL/MG, DG and TAG) in BeWo cells 
prestimulated with LXR agonist compared to controls. The known LXR target genes 
SREBP-1 and FAS were also highly induced upon LXR activation, and therefore 
suggest to be involved in the observed increased de novo fatty acid biosynthesis.  
We finally examined if activation of LXRs could affect expression and secretion of 
the glycoprotein hormone hCG during BeWo cell differentiation. Simultaneous 
incubation with LXR agonist and a differentiation agent (forskolin) throughout cell 
differentiation, produced a dose dependent reduction in expression and secretion of 
hCG.  
In conclusion, these results indicate that LXR has similar effects in placenta as in 
liver and adipose tissue on de novo fatty acid metabolism and further metabolism into 
complex lipids. Furthermore, the results suggest a role for the LXRs in regulation of 
trophoblast differentiation through the regulation of hCG.  
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3.2 Paper II: 
Activation of LXR increases fatty acid uptake through direct regulation of 
ACSL3 in placental trophoblast cells
Our results in Paper I encouraged us to further explore the role of LXRs in placental 
trophoblast cells. We therefore performed a microarray on human primary third 
trimester trophoblast cells incubated with LXR agonist (T0901317) or vehicle. 
Analysis of the microarray identified ACSL3 as a hitherto unknown LXR target gene, 
which was highly induced upon LXR agonist stimulation. Theoretical promoter 
analysis of the ACSL3 promoter identified a very promising LXRE. EMSA and 
transfection studies of the full length ACSL3 promoter and promoters without a 
functional LXRE identified ACSL3 as a direct LXR target gene.  
After establishing ACSL3 as a direct LXR target gene, we examined whether acyl-
CoA synthetase activity and fatty acid uptake was increased following LXR 
activation in BeWo cells. Incubation of BeWo cells with LXR agonist increased the 
activation of OA and the uptake of OA, EPA, DHA and ARA. To further test the 
importance of ACSL3 on fatty acid uptake and activation, we silenced ACSL3 in 
BeWo cells and incubated the cells with LXR agonist. The LXR-mediated induction 
of fatty acid uptake and activation was strongly inhibited in these cells. Interestingly, 
silencing of ACSL3 also reduced the basal fatty acid uptake by 30% and the basal 
acyl-CoA synthetase activity by 50%.  
In conclusion, our results show that LXR increase the uptake of LCPUFA. 
Furthermore, LXR increase the uptake and activation of OA through the direct 
induction of ACSL3 expression. Our results also identify ACSL3 as the main long 
chain acyl-CoA synthetase and a major fatty acid uptake protein in BeWo cells. 
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3.3 Paper III:
Expression of liver X receptors in pregnancies complicated by preeclampsia 
Preeclampsia is a pregnancy specific disorder associated with hyperlipidemia. Results 
from Paper I and II suggest that LXRs could be involved in regulation of lipid 
metabolism and uptake in human placenta. In Paper III we therefore wanted to 
investigate the expression of LXR and LXR in human term placental tissue in 
preeclampsia and uncomplicated pregnancies. We also analyzed placental tissue 
concentrations of lipids and the fatty acid profile in a subpopulation of these samples. 
Expression of LXR, LXR and fatty acid transporter CD36 was significantly 
decreased in placental tissues while increased expression was observed for LXR in 
adipose tissue from pregnancies complicated by preeclampsia. There was a positive 
correlation between placental LXR expression and placental free fatty acids in 
preeclampsia. Our results suggest a possible role for LXR and LXR as 
transcriptional regulators in the preeclamptic situation.  
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4. Discussion 
4.1 Methodological considerations 
4.1.1 Model systems 
In the papers included in this thesis, a human placental cell line, BeWo cells, and 
human term placental tissue were used to identify functions of the human placenta 
(Paper I, II and III). Supplemental information was obtained from human primary 
third trimester trophoblasts and other trophoblast cell lines (Paper I and II). We 
further used BeWo cells as a model system for trophoblast cells in several functional 
studies (Paper I and II).  
Cultured cell lines permit a high degree of control of the experimental settings. In 
addition, many cultured cell lines have retained properties of their origin, and 
therefore represent useful model systems for studies of cellular molecular biology. 
Primary human cells can be obtained from patients with different genetic, nutritional 
and metabolic background. Larger standard error is therefore expected in experiments 
using these cells than in cell line experiments. On the other hand, primary cells in 
culture are expected to represent a more physiologically “natural” model system.  
The BeWo cell line was the first commercial human trophoblast cell line to be 
developed (283). It was established from a malignant gestational trophoblast cancer 
(a choriocarcinoma), and has maintained many of the properties of primary 
cytotrophoblasts, such as the differentiation to syncytiotrophoblasts and secretion of 
hCG (284). Later, the cell line was also shown to have retained many of the 
properties of lipid transport and metabolism characteristic of human primary cyto- 
and syncytiotrophoblast cells. BeWo cells for example, have similar transport 
properties as primary trophoblasts, including a polarized transport of LCPUFAs and 
expression of many of the same genes involved in lipid metabolism (48;285;286). We 
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therefore believe that the BeWo cell line represents a good model system to study  
LXR-mediated regulation of lipid metabolism.  
The isolation of primary cytotrophoblast cells is more time-consuming and 
expensive, and primary cells are more difficult to keep in culture for longer periods 
compared to BeWo cells. We have therefore chosen to use BeWo cells as our 
principal cell model system in Paper I and II. Primary trophoblast cells were also 
used to supplement and confirm the results observed in BeWo cells (Paper II).  
Cell culture experiments are often supplemented with in vivo experiments. For these 
experiments, rodents are commonly used to obtain results from a more physiological, 
but still controllable laboratory setting. The access to the use of most human tissues 
for research purposes is limited. In placental research, the situation is quite different. 
There is an abundant access to human tissues, and although several general features 
of fetal nutrient uptake and utilisation are similar among mammalian species, major 
differences are present, especially concerning placental permeability. This is 
particularly important for research regarding lipid uptake and metabolism where 
permeability properties play a major role. These properties therefore limit the use of 
animal models in this field of human placental research. Species differences in lipid 
uptake and metabolism are reflected by a large species variation in fetal lipid 
accumulation during pregnancy. While fat constitutes 16% of body mass at birth in 
humans, it constitutes 10% in guinea pigs and only 2-4% in ruminants (reviewed in 
(2)). The net flux of fatty acid across the placenta also differs among species. In 
placentas having both maternal and fetal layers, such as sheep, pig and cat, the 
maternal fatty acid transfer is small (287-290), while in species in which the placenta 
is formed by layers of fetal origin, such as rabbit, rat, guinea pig and primates, the 
placental transport is much higher (290-295). It also appears that transport of 
individual FFAs across the placenta is determined largely by the placental 
characteristics of the species. While perfusion studies revealed little selectivity in the 
rate of transfer between different fatty acids in guinea pig and rabbits, similar studies 
in humans resulted in a preference for transfer of ARA and DHA (75;76;292;296). 
 51
On the basis of this information, we have therefore chosen not to use animal models 
for placenta studies in this thesis.  
4.1.2 LXR agonists 
At the initial stage of this work, the most common synthetic LXR agonist of that 
time, T0901317 (Paper I) was used. Later, when it was published that T0901317 
could interfere with farnesoid X receptor (FXR) and PXR signalling pathways, we 
replaced the use of T0901317 with that of the selective LXR/LXR agonist, 
GW3965 in our experiments (Paper II) (297;298). However, we cannot rule out the 
possibility that some of our findings in Paper I are not due to activation of PXR or 
FXR. Nevertheless, the confirmation of SREBP-1 and FAS induction by GW3965 in 
BeWo cells indicate reproducibility of some of the data with a new agonist 
(unpublished data and Paper II). 
4.1.3 The use of qRT-PCR 
During the last few years, quantitative real-time-polymerase chain reaction (qRT-
PCR) has essentially taken over from the traditional Northern blotting method for 
quantitative measurement of mRNA expression levels (Paper II and III as compared 
to Paper I). The combination of real time quantification with high levels of 
amplification permits fast, precise and accurate results. Modern qRT-PCR reactions 
produce a nearly exact doubling of product at every cycle in the exponential face of 
the reaction, in order to obtain a quantitative relationship between the amount of 
starting target sample and amount of PCR product produced per cycle. The 
amplification permits the detection of down to one copy of mRNA, but any 
experimental biases such as differences in RNA yields and PCR inhibition will effect 
the amplification. To compensate for such differences, there is a general agreement 
on normalizing the data to endogenous controls. The ideal endogenous control should 
be expressed at a constant level within the entire experiment, but unfortunately, no 
such universal endogenous control exists. If the endogenous controls are regulated it 
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could in the worst cases produce results reflecting the regulation of the endogenous 
control, not that of the target gene (Figure 9). Each new cell and tissue experiment 
should therefore be accompanied by the test of endogenous controls to ensure the use 
of a control with constant expression levels throughout the experiment.  
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Figure 9: Expression of ACSL1 in untreated BeWo cells and human term placenta using 
three different endogenous controls, or no endogenous control. cDNA was synthesized from 
BeWo cell and human placenta total RNA. qRT-PCR was run using cDNA from equal 
amount of measured total RNA. The following assays were used: ACSL1, Hs00960561_m1; 
Beta-2-microglobulin (B2M), Hs99999907; Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), Hs99999905_m1; ribosomal protein L27 (RPL27), Hs01594520_m1. All 
materials were from Applied Biosystems, and the methods were run according to the 
manufacturer's instruction. Results were quantified using the Ct and Ct method. n = 3. 
Mean ± SEM is shown.  
Unfortunately, more commonly than not, information on the testing of endogenous 
controls are not presented in published papers. In this thesis, each new experimental 
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setting has been accompanied by thorough testing of several endogenous controls to 
ensure the use of a non-regulated one (Paper II and III). When comparing basal 
expression in different tissues or cell lines, we were not able to find non-regulated 
endogenous controls (Figure 9). By assuring linearity between mRNA to 
complementary DNA (cDNA) and cDNA to PCR conversion, we ended up not using 
any endogenous control when comparing the expression between different tissues, 
assuming that equal amount of total RNA added to each well, represented equal 
amplification (Paper III). Although unusual to do, we believe this method represents 
a more correct normalization than using a regulated endogenous control, in our 
setting.  
4.1.4 Problems with gene correlation studies using LDA cards 
Low density arrays (LDA) have recently become commercially accessible and thus 
efficient new tools for detection of multiple genes simultaneously using qRT-PCR 
technology have become available. The access to the transcriptional information of 
dozens of genes when studying clinical materials as in Paper III, provides a good 
possibility to run correlations between the genes to search for statistically significant 
and possibly biological relevant correlations between genes. We were interested in 
running correlations between placental LXR or LXR expression and placental 
expression of genes that are known LXR target genes in other tissues. Our intention 
when running the LXR-target gene correlation was to look for possible biological 
functions of the LXRs in placenta. Unfortunately, we came to the conclusion that we 
could not trust such a statistical use of our expression data. We observed a surprising 
number of biologically plausible significant correlations. As a control we further 
tested the correlation between genes that we did not believe had any biological 
correlation (e.g. endogenous controls), and the same surprising number of significant 
correlations was found between these genes. Our material was found to have linearity 
between total RNA, cDNA and PCR synthesis and potential PCR inhibition was not 
detected (Paper III). However, as with the run of any LDA cards, all the gene 
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expression data from every patient came from the same sample. Therefore, there was 
not a random distribution of technical differences between the genes analyzed in each 
sample. These systematic biases were probably so strong that whatever biological 
correlation present was impossible to distinguish from the technical differences in 
each sample.  
However, the data are excellent for analysis of average gene expression, because in 
this case the technical variation is not systematic. Confounding factors are present in 
any laboratory experiment, but are not usually of any significance for the results 
because they are not systematically distributed. If separate sample handling all the 
way from taking the biopsy to the running of the qRT-PCR and single genes were 
performed, the use of correlation between genes could have been possible, but very 
time-consuming.  
4.1.5 Gestational age 
There is a significant difference in gestational age between our two study groups in 
Paper III, with the preeclamptic group delivering earlier than the control group. 
However, avoiding a gestational difference between prematurely delivered PE and 
term-delivered uncomplicated pregnancy is clinically not feasible when sampling 
placental tissue. This is due to the fact that premature deliveries of uncomplicated 
pregnancies are ethically unacceptable and therefore not available as a control group. 
If a baby and placenta is delivered prematurely, it is normally due to pathological 
conditions, such as inflammation/infection and therefore not suitable as a control. 
Correcting for gestational age is mathematically possible but it is not necessarily 
biologically correct, as premature delivered women with preeclampsia will generally 
have a more severe form of the disease than women delivered at term (100). Still we 
cannot exclude that differences in gestational length between the study groups could 
potentially affect our results and conclusions in Paper III.  
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4.2  Discussion of results 
4.2.1 Roles for the LXRs in lipid metabolism in placenta  
Numerous LXR target genes have been identified in tissues involved in lipid 
metabolism, such as liver, muscle and adipose tissue. When considering that the 
human placenta is secreting 50-200 times more fatty acids than rat hepatocytes, we 
expected LXRs to have a regulatory role in controlling lipid metabolism in placenta 
(26). Our initial analyses of SREBP-1c, FAS and LXR suggested a role of LXR in 
lipogenesis in human placental BeWo cells (Paper I). To further understand the role 
of LXRs in placenta, we performed microarray and qRT-PCR on total RNA isolated 
from human term placental trophoblast cells stimulated with the synthetic LXR 
agonist, T0901317 (unpublished data and Paper II). These data confirmed the 
induction of SREBP-1 and FAS gene expression in primary trophoblast (Paper II and 
unpublished data) observed in BeWo cells (Paper I). In addition, the expression of 
other known direct LXR target genes was induced (~6-fold induction of SCD-1, ~4-
fold induction of ABCG1, ~3-fold induction of ABCA1 and an ~2.5-fold induction of 
ACC). This demonstrates a major regulatory role for LXRs in placental trophoblast 
cells apart from other metabolic tissues, such as macrophages, adipose tissue and 
liver (unpublished data, (198)). The microarray analysis further revealed several 
hitherto unknown potential LXR target. One of these genes, lipin-1, was investigated 
further. However, theoretical promoter analysis and gene expression studies in BeWo 
cells and LXR -/-/ -/- mice suggested that it is not a direct LXR target gene 
(unpublished data). Then, ACSL3 was also identified as a potential LXR target gene, 
which was induced by the LXR agonist T0901317, on the microarray. Theoretical 
analysis of the ACSL3 promoter, using a consensus LXRE element, identified a 
potential theoretical LXRE, which was shown subsequently to be functional (Paper 
II). Further analysis in liver, muscle and adipose tissue in mice suggested that this 
regulation was not restricted to placenta (Figure 10).  
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Figure 10: LXR mediate regulation of ACSL3 in different tissues in mice. Male LXR +/+/ 
+/+ and LXR -/- -/- mice were gavaged with vehicle (1% CMC) or T0901317 (30 mg/kg) 24 
hours prior to scarification. Total RNA (Trizol, Invitrogen) from liver, skeletal muscle, heart 
and white adipose tissue were analyzed for expression of Acsl3 (Mm01255804_m1) and Fas 
(Mm00662319_m1) by qRT-PCR (all from Applied Biosystems, according to the 
manufacturers instructions) normalized to Tbp (Mm00446973_m1). The results are 
presented as mean ±SEM, relative to control (n = 4-6 for each group). P-values * < 0.05 and 
** < 0.01 C).  
In addition to differential expression of target genes in both primary trophoblasts and 
BeWo cells, we identified an  LXR-mediated increased de novo fatty acid 
biosynthesis, increased uptake of several types of fatty acids (OA and LCPUFAs) and 
increased concentrations of FFA and complex lipids such as TAG, phospholipids and 
cholesteryl esters in BeWo cells (Figure 11, Paper I and II). These results are in line 
with the observed increased LXR-mediated expression of SREBP-1, FAS and 
ACSL3 in BeWo cells and primary trophoblasts (Figure 11, Paper I and II). We did 
not observe increased -oxidation of fatty acids when incubating BeWo cells with 
LXR agonist (unpublished data). The expression of genes leading to increased uptake 
and lipogenesis and lack of regulation of -oxidation, suggests LXR as a regulator of 
anabolic pathways of lipid metabolism in placental trophoblast cells. All these above 
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multiple roles of LXR suggest a coordinating role of LXR in lipid metabolism in 
placental trophoblast cells and perhaps in placental tissues (figure 11).  
 
 
 
 
 
 
 
 
Figure 11: Effects of LXR on human placental trophoblast cells. Summery of Paper I and II. 
The influence of LXR is marked with +. The results obtained from each paper is indicated (I 
= Paper I, and II = Paper II).  
 
Numerous observations in this thesis demonstrate overlapping functions between the 
regulatory roles for LXR in placenta and other lipid metabolizing tissues. Although 
the regulation in different tissues appears to be similar, the physiological role could 
be quite different. ACSL3 is highly expressed in placenta, brain and intestine and in 
inguinal adipose tissue (153). Based on the LXR-mediated ACSL3 induction 
observed in several tissues (Figure 10), we suggest that a similar LXR-mediated 
regulation of ACSL3 could also have important roles in tissues with high levels of 
ACSL3 expression. The physiological consequences of such a regulation could differ 
depending on the function of the tissue. The ACSL3-mediated uptake of LCPUFAs 
in brain could be important for the high need for LCPUFAs in this organ during fetal 
development (60). In the intestine, the regulation could be important for LCPUFAs 
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uptake from the diet. In lymph node-containing adipose tissues such as the inguinal 
adipose tissue, LCPUFA uptake play a role in the interaction with the immune system 
(reviewed in (299)). Increased PUFA accumulation has been reported in node-
containing tissues, and is thought to be important for the production of prostaglandins 
and leukotriens (300). 
Insulin has a major effect on lipid metabolism in liver, muscle and adipose tissue, and 
LXR is upregulated by insulin. LXR is involved in insulin-mediated upregulation of 
SREBP-1, and so it would have been interesting if LXR-insulin stimulation had any 
influence on placental gene expression (246). However, when performing microarray 
on primary human trophoblasts incubated with insulin alone or insulin and T0901317 
together, no insulin-mediated regulation of any genes was observed compared to the 
respective controls (cells incubated with T0901317 alone, or cells incubated without 
T0901317 or insulin added; unpublished data). Limited impact of insulin on placental 
lipid metabolism function has also been reported previously (301). The lack of 
response to insulin also indicates major differences between placenta and other lipid 
metabolizing and insulin sensitive tissues such as adipose tissue, muscle and liver in 
terms of LXR regulation.  
4.2.2 LXR and ACSL3 functions on lipid droplets 
Our research group has previously observed an increase in lipid droplet size when 
incubating preadipocytes with LXR agonist during differentiation to adipocytes, but 
the mechanisms behind this increase are not fully understood (225). ACSL3 is one of 
the main proteins associated with lipid droplets in hepatocytes, and the concentration 
of ACSL3 on lipid droplets correlated with the TAG biosynthesis in Huh7 
hepatocytes (155;156). The identification of ACSL3 as a direct LXR target gene 
(Paper II) and the presence of this regulation in adipose tissue (Figure 10) therefore 
suggests a possible mechanism for the observed LXR-mediated increase in lipid 
droplet size in adipocytes, and perhaps also in other tissues. The localisation of 
ACSL3 on the lipid droplet would then perhaps increase the uptake and activation of 
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fatty acids and thereby increasing the production of TAG and the size of lipid 
droplets. A plasma membrane location of ACSL3 is possibly not necessary for the 
fatty acid uptake function of this gene as fatty acid uptake mediated by FATP4 has 
been reported to occur by FATP4 proteins exclusively located on intracellular 
organelles (140). ACSL3 could be involved in the channelling of fatty acids for TAG 
biosynthesis and further storage in lipid droplets. This suggests that ACSL3 together 
with LXR could have an important role in protecting cells from toxic effects of FFA 
and subsequent insulin resistance in tissues such as liver, muscle or adipose tissue.  
4.2.3 LXR in preeclampsia and atherosclerosis 
To the best of our knowledge, there is no information available on the levels of 
endogenous LXR agonists (oxysterol) in placenta in preeclampsia. In Paper III we 
observed a highly significant downregulation of both LXRs in preeclamptic placentas 
as compared to controls. An autoregulation of LXR has been described in some 
tissues including BeWo cells (Paper I, (302;303)), suggesting that this autoregulation 
is present in placenta. Dyslipidemia, including increased oxLDL is a common feature 
of preeclampsia (110). It could perhaps result in increased placental concentrations of 
endogenous LXR agonists. However, the reduced placental expression of both LXRs 
in preeclampsia compared to uncomplicated pregnancies in Paper III suggests that 
there is not an increased placental concentration of LXR agonists in preeclampsia. 
Combined with reduced LXR expression, this suggests a reduced LXR activity in the 
preeclamptic placenta. However, ligand-independent factors such as cofactor-
interaction, and post-translational modifications of LXRs could also be important for 
the regulation of placental LXR expression and activity in preeclampsia.  
Preeclampsia and cardiovascular disease have many risk factors in common including 
endothelial dysfunction, obesity, insulin resistance, hypertension and dyslipidemia 
(110;112;113;304). There are strong indications for a protective role of LXR in 
atherosclerosis by the reverse cholesterol transport of endothelial cells and 
macrophages. The reduced expression of both LXRs in preeclamptic placentas (Paper 
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III) could result in a reduced reverse cholesterol transport from placental 
macrophages and endothelial cells. Endothelial dysfunction is a common feature of 
preeclampsia and plaque formation is observed in acute atherosis in Preeclampsia 
(115). Therefore, we speculate that the reduced expression of LXR may exacerbate 
these "atherogenic" characteristics of preeclampsia. We did not however observe a 
correlation between total placental cholesterol levels and LXR or LXR expression 
in placenta (Paper III). Separate analysis of cholesterol and cholesteryl ester levels in 
placental macrophages and endothelial cells would be necessary to clarify this issue.  
Our gene expression data from preeclamptic and control placentas suggest that LXR 
is not the main regulator of many known LXR target genes in placenta in 
Preeclampsia (Paper II). Although not anticipated, the results are not surprising, as 
complex mechanisms involving many unknown factors are involved in the regulation 
of genes. The identification of a gene as an LXR target gene in one tissue under 
certain conditions is therefore just an indication of a functional relationship between 
these genes in other tissues and conditions. Especially in a clinical situation, with 
many unpredictable potential regulatory factors, it is often difficult to predict the 
regulation of any gene based on such knowledge.  
4.2.4 Is there a lipid metabolism independent role for the LXRs in 
placenta? 
Regulatory roles for LXRs apart from lipid metabolism have been reported in 
macrophages (196;305;306). Pavan et al (279) and our results on hCG in Paper I also 
indicate a non-lipid metabolic role for LXR in placenta. Pavan et al showed that LXR 
activation inhibits a cell model of first trimester trophoblast invasion. This is in line 
with our observation of an inhibitory  LXR-mediated regulation of hCG, as hCG is 
important for the retaining of the implanted blastocyst in the uterine wall (Paper I). 
Furthermore, in Paper I we observed increased expression of LXR during BeWo cell 
differentiation from cyto- to syncytiotrophoblasts. hCG is reported to increase 
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differentiation of trophoblasts (12). These findings suggest that LXR could be 
involved in inhibiting trophoblast differentiation from cyto- to syncytiotrophoblasts. 
Many genes involved in inflammation are reported to be increased in preeclampsia 
and many of these genes are down regulated by LXRs. These genes include inducible 
nitric oxide synthase, COX-2, matrix metallopeptidase-9, interleukin 6 and tumour 
necrosis factor  (196;305;306). Thus, it is possible that LXR has hitherto 
unrecognized roles in placenta in preeclampsia. 
4.2.5 ACSL3 in placenta 
ACSL3 appears to have a central position in fatty acid activation and transport in 
placental trophoblast cells, but also ACSL1 and ACSL4 were highly expressed in 
these cells in our study (Paper II). However, our data suggest that ACSL3 is the main 
ACSL involved in fatty acid activation in placental trophoblast cells, as silencing of 
ACSL3 reduced the total oleoyl-CoA synthetase activity by 50% in BeWo cells 
(Paper II). Silencing of ACSL3 further reduced the basal fatty acid uptake by 30% in 
BeWo cells (Paper II). Silencing of ACSL3 could be accompanied by a compensatory 
increase in one or more of the other ACSLs, as is often observed between 
homologous genes in lipid metabolism. We did however not observe any alternations 
in the mRNA expression of any members of the ACSL family when ACSL3 was 
silenced in BeWo cells (unpublished data). Thus, ACSL3 appears to have a unique 
role in trophoblast cells that cannot be compensated by other members of the ACSL 
family, and this suggests a predominant role of ACSL3 in placental fatty acid uptake 
and metabolism.  
Activation of PPAR,  and , that are key regulators of numerous genes involved in 
fatty acid transport and lipid metabolism, did not have any effect on ACSL3 
expression in BeWo cells (unpublished data). These results agree with another study 
which showed that activation of PPAR had no effect on ACSL3, but increased the 
expression of ACSL1 in rodent heart (307;307).  
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Although insulin, fatty acids, oncostatine and Vitamin D3-mediated regulation of 
ACSL3 has been reported (307-309), to the best of our knowledge our analysis is the 
first to demonstrate that ACSL3 is being directly regulated through any identified cis-
regulatory element in the promoter (an LXRE, Paper II).  
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5. Conclusions 
 
The conclusions from the present study can be summarized by listing the following 
main findings: 
1. LXR and LXR are expressed in placenta and BeWo cells (Paper I and III). 
2. LXR activation increases de novo fatty acid synthesis, fatty acid activation and 
fatty acid metabolism into complex lipids in BeWo cells (Paper I and II). 
3. LXR activation decreases the expression and secretion of hCG from BeWo 
cells (Paper I). 
4.  LXR activation increases the uptake of OA and LCPUFAs in BeWo cells 
(Paper II). 
5. ACSL3 is a direct LXR target gene in BeWo cells (Paper II). 
6. LXR-mediated increased fatty acid uptake and activation are dependent on 
ACSL3 (Paper II). 
7. LXR and LXR are downregulated in preeclamptic placentas compared to 
placentas from uneventful pregnancies (Paper III). 
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